Omecamtiv Mecarbil as an emerging therapeutic alternative in the management of heart failure [Omecamtiv Mecarbil como alternativa terapéutica emergente en el abordaje de la insuficiencia cardíaca]
DOI:
https://doi.org/10.62574/g7pyr688Keywords:
heart failure, cardiotonics, therapyAbstract
Objective: To analyse the use of Omecamtiv Mecarbil as an emerging therapeutic alternative in the treatment of heart failure. Method: Analytical observational literature review of 16 scientific articles. Results and conclusion: Omecamtiv Mecarbil has been shown to be effective in improving myocardial contractility without significantly increasing oxygen consumption, positioning it as an innovative alternative to traditional inotropic drugs, which often have adverse effects related to increased myocardial oxygen demand.
Downloads
References
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
Patel PH, Nguyen M, Rodriguez R, Surani S, Udeani G. Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management. Cureus [Internet]. 2021; Disponible en: https://www.cureus.com/articles/47520-omecamtiv-mecarbil-a-novel-mechanistic-and-therapeutic-approach-to-chronic-heart-failure-management
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail. 2021;23(3):352–80.
Aksel T, Choe Yu E, Sutton S, Ruppel KM, Spudich JA. Ensemble Force Changes that Result from Human Cardiac Myosin Mutations and a Small-Molecule Effector. Cell Rep. 2015;11(6):910–20.
Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, et al. Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin. ACS Med Chem Lett. 2010;1(9):472–7.
Auguin D, Robert-Paganin J, Réty S, Kikuti C, David A, Theumer G, et al. Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction. Nat Commun. 2024;15(1):4885. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11161628/
Abella LMR, Höhm C, Hofmann B, Gergs U, Neumann J. Effects of omecamtiv mecarbil and mavacamten in isolated human atrium. Naunyn-Schmiedeberg’s Arch Pharmacol. 2023;396(3):499–511. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9898377/
Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, et al. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. J Am Coll Cardiol. 2016;67(12):1444–55. Disponible en: https://www.sciencedirect.com/science/article/pii/S073510971600351X?via%3Dihub
Teerlink JR, Felker GM, McMurray JJV, Solomon SD, Adams KF, Cleland JGF, et al. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388(10062):2895–903. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32049-9/abstract
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021;384(2):105–16. Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa2025797?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Lewis GD, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, et al. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. JAMA. 2022;328(3):259. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9297119/
Zhou S, Liu Y, Huang X, Wu C, Pórszász R. Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future. Front Cardiovasc Med. 2024;11:1337154. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10985333/
Tromp J, Ouwerkerk W, Van Veldhuisen DJ, Hillege HL, Richards AM, Van Der Meer P, et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73–84. Disponible en: https://www.sciencedirect.com/science/article/pii/S221317792100442X?via%3Dihub
Alqatati F, Elbahnasawy M, Bugazia S, Ragab KM, Elsnhory AB, Shehata M, et al. Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis. Indian Heart J. 2022;74(3):155–62. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9243594/
Ráduly AP, Tóth A, Sárkány F, Horváth B, Szentandrássy N, Nánási PP, et al. Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca2+ levels. ESC Heart Fail. 2023;10(2):1326–35. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10053277/
Fülöp GÁ, Oláh A, Csipo T, Kovács Á, Pórszász R, Veress R, et al. Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans. Basic Res Cardiol. 2021;116(1):24. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8041714/
Downloads
Published
Issue
Section
License
Copyright (c) 2025 María Gabriela Balarezo-García , Diego Armando Suárez-Páez , Melany Jhaslady Moreano-Camalli , Rafael Josafat Viteri-Paredes (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
